What Aroa Biosurgery does

Aroa Biosurgery Limited is an ASX-listed (ASX: ARX) New Zealand-based soft-tissue repair medtech company that develops and commercializes regenerative bioscaffolds built on its proprietary AROA ECM™ extracellular matrix platform technology. Its product portfolio includes the Myriad family (Matrix, Morcells, Morcells Fine, Meshed) for complex wounds, trauma, and reconstruction; Endoform™ for acute and chronic wound management; Reinforced Bioscaffolds for hernia repair and abdominal wall reconstruction; and Symphony™, a combination cellular and tissue product (CTP) combining AROA ECM™ with hyaluronic acid, currently advancing through a randomized controlled trial in diabetic foot ulcers.

The company generates revenue primarily through one-time sales of its bioscaffold devices to hospitals, trauma centers, and surgical centers via a direct, sales-led enterprise field motion, with the United States identified as the primary growth geography. In H1 FY26, Aroa reported NZ$19.7 million in revenue (up 33% year-over-year) and its first profitable half-year at NZ$1.8 million EBITDA, with Myriad contributing 44% of product sales. Clinical validation is anchored by the MASTRR study (49 patients across four US Level One trauma centers, zero device-related complications, median 22.5 days to full vascularized tissue coverage) published in the Journal of Trauma and Injury, and the Symphony RCT meeting its primary endpoint in diabetic foot ulcer patients.

Aroa operates with 101-250 employees and targets multiple large addressable markets — a US$450 million US trauma opportunity cited by analysts, a USD 1.33–2.25 billion global regenerative tissue matrix market by 2035 (5.4% CAGR), a USD 2.63 billion biologic hernia repair mesh market by 2030, and a USD 0.84 billion breast reconstruction mesh market by 2030. Four analysts maintain a Strong Buy rating on the stock with an A$0.85 consensus price target versus a current price of A$0.72.

Name

Aroa Biosurgery

Legal name

Aroa Biosurgery Limited

Website

https://aroabio.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

101–250 employees

Short description

Aroa Biosurgery is an ASX-listed New Zealand medtech company that develops and sells regenerative soft-tissue repair bioscaffolds built on its proprietary AROA ECM™ platform, sold primarily to US hospitals, trauma centers, and surgeons for wound care, reconstruction, and hernia repair applications.

Ownership category

akta.pro rank

Product category

Regenerative Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Biologics & Biosimilars Distributors (HLAIAJAH), Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers) (HLAGAIAG)

Keywords

• Soft tissue repair
• Regenerative bioscaffolds
• Extracellular matrix devices
• Wound care products
• Hernia repair mesh

Headquarters

HQ city

Auckland

HQ country

New Zealand

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Technology or R&D, Personnel, Marketing or Sales, Supply Chain

Revenue model

1. Medical device / bioscaffold product sales: Aroa generates revenue primarily through one-time sales of its soft tissue repair bioscaffolds to hospitals and surgical centers. Reported NZ$19.7 million revenue for the half-year period (up 33% year-over-year), with the Myriad product line representing 44% of product sales.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

Aroa Biosurgery develops, manufactures and commercializes regenerative soft tissue repair bioscaffolds built on its proprietary AROA ECM™ extracellular matrix platform technology. Its portfolio includes the Myriad family of surgical bioscaffolds, Endoform™ for acute and chronic wounds, Reinforced Bioscaffolds for hernia repair and abdominal wall reconstruction, and Symphony™, a combination cellular and tissue product for difficult-to-heal wounds such as diabetic foot ulcers. Products are FDA-cleared and sold to hospitals, trauma centers and surgeons, primarily in the United States.

Product overview

Aroa Biosurgery offers a platform-plus-modules portfolio centered on its proprietary AROA ECM™ (extracellular matrix) platform technology, which underpins a range of soft tissue repair products aimed at unlocking regenerative healing. The portfolio includes the Myriad family of surgical bioscaffolds (Myriad Matrix™, Myriad Morcells™, Myriad Morcells Fine™, and Myriad Meshed™) for complex wounds, trauma, and reconstruction; Endoform™ for acute and chronic wound management; Reinforced Bioscaffolds targeted at hernia repair and abdominal wall reconstruction; and Symphony™, a combination cellular and tissue product combining AROA ECM™ with hyaluronic acid, under clinical evaluation as a skin substitute for difficult-to-heal wounds such as diabetic foot ulcers.

Differentiator

Problem solved

Functional benefit

Brands

• Endoform™: Restorative bioscaffolds for the management of acute and chronic wounds.
• Myriad Matrix™
• Myriad Morcells™
• Myriad Morcells Fine™
• Myriad Meshed™
• Symphony™
• Reinforced Bioscaffolds

Products and services

• Myriad Matrix™ Surgical soft tissue bioscaffold built on the AROA ECM™ platform technology, designed for complex wounds and reconstruction applications including trauma and acute care surgery. Sold to hospitals, trauma centers and surgeons.
• Myriad Morcells™ Configuration of the AROA ECM™ bioscaffold platform technology for soft tissue repair. Sold to hospitals and surgical centers.
• Myriad Morcells Fine™ Finer configuration variant of the Myriad Morcells™ bioscaffold offering within the AROA ECM™ platform. Sold to hospitals and surgical centers.
• Myriad Meshed™ Fenestrated configuration of the AROA ECM™ bioscaffold providing a meshed form factor for soft tissue repair. Sold to hospitals and surgical centers.
• Symphony™ Combination cellular and tissue product (CTP) comprising AROA ECM™ with hyaluronic acid, under clinical evaluation as a skin substitute for difficult-to-heal wounds including diabetic foot ulcers. Sold to hospitals and wound care specialists.
• Endoform™ Restorative bioscaffold used in the management of acute and chronic wounds. Sold to hospitals, wound clinics and surgical centers.
• Reinforced Bioscaffolds AROA ECM™-based bioscaffolds designed specifically for hernia repair and abdominal wall reconstruction, providing additional reinforcement for high-tension applications. Sold to hospitals and general/reconstructive surgeons.

Quantifiable outcome

• Zero device-related complications and full vascularized tissue coverage in median 22.5 days in the MASTRR study across 49 patients
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Scale indicators12 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Organogenesis Holdings: Public US-listed regenerative medicine company focused on wound care and surgical biologics (e.g., Apligraf, Dermagraft, PuraPly). Directly comparable to Aroa as a competing seller of skin substitutes and regenerative soft-tissue products to US hospitals and wound care clinics.
• Integra LifeSciences: Public global medical device company with a dedicated Regenerative Technologies portfolio (e.g., Integra Dermal Regeneration Template, AmnioExcel) that competes head-to-head with Aroa's AROA ECM™-based bioscaffolds in wound reconstruction and soft-tissue repair.
• MiMedx Group: Public US-listed regenerative medicine company selling dehydrated amniotic membrane allografts (e.g., EpiFix, AmnioFix) for wound care and surgical applications. Comparable to Aroa in business model, end customers (US hospitals and wound centers), and indication focus (chronic wounds, surgical recovery).

Broad incumbents

• Smith & Nephew: Large-cap global medical device incumbent with a substantial Advanced Wound Management portfolio (e.g., Allevyn, PICO). Competes with Aroa for hospital wound care budget and represents a broader, well-funded incumbent that Aroa must displace at US trauma centers.
• Coloplast: Global Danish medical device company with a dedicated Wound & Skin Care business (e.g., Biatain, Conveen). Comparable to Aroa as a wound care incumbent addressing chronic wounds and skin substitutes in hospitals, though with a much broader product portfolio.
• ConvaTec: Public global medical products company with an Advanced Wound Care franchise (e.g., Aquacel, Foam dressings). Comparable to Aroa as a competitor selling wound management products into US hospitals and a public peer against which Aroa's growth and margins can be benchmarked.
• Becton, Dickinson and Company (BD): Large-cap global medical technology company with a Biosciences and Medical Surgery portfolio that includes wound closure, biosurgery, and tissue products. Comparable to Aroa as a broad incumbent with overlapping biosurgery categories and the scale to influence US hospital procurement.

Emerging players

• ACell: US-based regenerative medicine company marketing MatriStem urinary bladder matrix products for wound management and surgical applications. Closely comparable to Aroa's AROA ECM™ bioscaffold concept (porcine-derived ECM scaffolds) and a direct competitor in complex wound healing.
• MTF Biologics: Non-profit tissue bank that develops and distributes allograft-based wound care and surgical products (e.g., AmnioBand, AlloPatch). Comparable to Aroa in offering biologic wound healing solutions to US hospitals, with overlapping indication coverage.
• Cook Biotech: US-based developer and manufacturer of extracellular matrix products (e.g., Biodesign hernia grafts, Oasis wound matrix). Highly comparable to Aroa in technology approach (ECM-based scaffolds) and indication focus (hernia repair, wound management).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aroa-biosurgery-limited
• Xx.com/AroaBiosurgery
• Facebookfacebook.com/AroaBiosurgery

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aroa Biosurgery